Vivani Medical & Okava Pharmaceuticals Extend Collaboration to Develop OKV-119 for Canine Cardiometabolic Diseases
Shots:
- Vivani Medical & Okava Pharmaceuticals have expanded their 2019 collaboration to develop OKV-119 for cardiometabolic conditions in dogs, which initially focused on cats
- Financial terms of the expanded agreement remain undisclosed but incl. future milestones & royalty payments to Vivani
- OKV-119 (GLP-1 receptor agonists) uses Vivani’s NanoPortal tech for steady drug delivery over time from a single implant & mimics physiological effects of fasting like improved insulin sensitivity, reduced fat mass, & improved metabolism without changing feeding routine in animals
Ref: Globenewswire | Image: Vivani Medical & Okava
Related News:- The US FDA Approves Zoetis’ Simparica Trio to Prevent Flea Tapeworm Infections in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
